RXST Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -12.2%, SMA50 -24.75%, SMA200 -25.65%). The stock’s 14-day RSI is 31.11 (weak momentum), while the ATR of 0.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -75.81% below its high and over 23.42% above its low. Average 10-day trading volume of 1.00 million shares is in line with the 3-month average of 914.06 thousand, indicating normal recent market interest.

RxSight, Inc. has 40.92 million shares outstanding. The public float is 32.44 million shares, elevated short interest at 14.81% of float. This equals 5.77 million shares. The short ratio is 4.86 days. Institutional investors hold 102.64% of the float. Insiders own 5.56%. Kurtz Ronald M MD holds 764.61 thousand shares, Weinberg Eric has 299.98 thousand shares and Goldshleger Ilya has 42.25 thousand shares.

Wall Street analysts project EPS growth of -14.11% annually over the next five years. The latest quarter delivered EPS of -$0.04. The next quarter is forecast at -$0.33. Next year's EPS is expected at $18.19. Analyst sentiment is neutral. Analyst rating data shows there are 1 Strong Buy ratings, 6 Buy ratings, 16 Hold ratings, 0 Sell rating and 3 Strong Sell ratings. Price targets range from $43.00 to $8.00. The high target offers 451.28% upside. The low target suggests 2.56% downside. The mean target is $18.69. This offers 139.62% upside. RxSight, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 05, 2025, missed forecasts by -78.95%. The prior quarter beat by -20.0%. Over the last six quarters, Apple has recorded several small beats. These include 125.83% in August 05, 2024.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

RxSight, Inc. (NASDAQ:RXST) closed at $7.80 USD, losing -$0.23 (-2.80%) from the previous close of $8.03. The stock is currently mid-range between its 52-week high and low $6.32 and $32.24. With a market capitalization of about $320.71 million, RxSight, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.13). Key stats such as the average daily volume over the past year has been around 953.44 thousand shares, in line with its 52-week average. Headquartered in Aliso Viejo, CA, RxSight, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Ronald Kurtz, the company employs approximately 498 people and listed since July 30, 2021. RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally.

RxSight, Inc. trades at a P/E ratio of -8.94, slightly below the S&P 500 average, with a price-to-sales ratio of 2.26 and a price-to-book ratio of 1.16 suggesting the stock is closer to book value. The P/FCF stands at -14.45, also above market averages.

Our AI price prediction model suggests that RxSight, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.08%, with price expected at $7.17 by February 25, 2026, within a range of $6.71 to $7.65 3-Month Outlook: Projected fall of -35.0%, reaching $5.07 by May 12, 2026, with a range of $4.53 to $5.82. 1-Year Outlook: Projected loss of -12.69%, with price at $6.81 by February 11, 2027, within a range of $0.00 to $2.48.

RxSight, Inc. (NASDAQ:RXST) shares are flat -7.29% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows RxSight, Inc. trading at a premium to the broader market with a P/E of -8.94. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $32.49, suggesting 316.54% upside. Our AI forecast model points to short-term weakness (-8.08% over two weeks), a medium-term fall (-35.0% over three months), and a longer-term loss (-12.69% over one year), with expected trading ranges indicating moderate volatility.